Accession Number:

ADA624452

Title:

Mindfulness-Based Relapse Prevention for Substance Use Disorders: A Systematic Review

Descriptive Note:

Research rept.

Corporate Author:

RAND NATIONAL DEFENSE RESEARCH INST SANTA MONICA CA

Report Date:

2015-01-01

Pagination or Media Count:

80.0

Abstract:

This systematic review aims to synthesize evidence from trials of Mindfulness-Based Relapse Prevention MBRP to provide estimates of its efficacy and safety for substance use disorders PROSPERO record CRD42015016380. In December 2014, we searched PubMed, PsycINFO, AMED, CINAHL, CENTRAL, Web of Science, and bibliographies of existing systematic reviews and included studies to identify English-language randomized controlled trials RCTs evaluating the efficacy and safety of MBRP used adjunctively or as monotherapy to treat substance use disorders in adults diagnosed with alcohol, opioid, stimulant, andor cannabis use disorder. Two independent reviewers screened identified literature using predetermined eligibility criteria, abstracted prespecified study-level information and outcome data, and assessed the quality of included studies. Outcomes of interest included relapse, frequency and quantity of substance use, withdrawalcraving symptoms, treatment dropout, functional status, health-related quality of life, recovery outcomes, and adverse events. When possible, meta-analyses were conducted using the Hartung-Knapp-Sidik-Jonkman method for random-effects models. Strength of evidence was assessed using the GRADE approach. Six studies reported in 20 publications with 685 participants were included. Evidence was insufficient to determine whether MBRP effects differ by type of substance use targeted. There were no significant effects for MBRP as an adjunctive therapy or a standalone monotherapy for most outcomes we did find some evidence in support of MBRP evaluated as an adjunctive therapy based on one RCT with regard to quality of life SMD 0.65 CI 1.20 to 0.10 1 RCT very low quality evidence and legal problems SMD 1.20 CI 1.78 to 0.62 1 RCT, very low quality evidence, yet these outcomes were not measured in any RCTs of MBRP as a monotherapy to serve as a comparison with effects for MBRP as an adjunctive therapy.

Subject Categories:

  • Psychology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE